PRELUDE CAPITAL MANAGEMENT, LLC
Position in TBPH — Theravance Biopharma, Inc.
CIK 1387508
NEW YORK, NY
Position in TBPH
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$405,750
New position
Shares Held
25,000
first reported quarter
Ownership
0.048%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 100%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026PRELUDE CAPITAL MANAGEMENT, LLC holds $45,146,517 across 96 Biotechnology names. TBPH ranks #32 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PGEN |
Precigen, Inc.
|
1,270,053 | $4,915,105 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
111,593 | $3,091,126 | |
| 3 | PRAX |
Praxis Precision Medicines, Inc.
|
9,064 | $2,920,330 | |
| 4 | COGT |
Cogent Biosciences, Inc.
|
64,222 | $2,471,904 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
29,658 | $2,227,019 | |
| 6 | ELVN |
Enliven Therapeutics, Inc.
|
52,578 | $2,061,057 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
17,073 | $1,660,349 | |
| 8 | ALMS |
Alumis Inc.
|
74,758 | $1,646,918 |
All Filings in TBPH
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $405,750 | 25,000 | Shares | Other | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||